-
You have just examined a young woman who reports she has had recent multiple sexual partners and says she has used irregular protection against sexually transmitted disease (STD). You order lab tests, including a screen for chlamydia. When positive results return the next day, will she come back for treatment?
-
In July 2003, the Office of Population Affairs (OPA) at the U.S. Department of Health and Human Services formally requested applications for $49 million for family planning service delivery under the Title X program for FY 2004. The announcement contains a number of new program priorities that will affect the delivery of subsidized family planning services for millions of low-income women and teens in the years to come.
-
-
In recent years, efforts to address substance abuse among pregnant women have moved from being barely visible public health initiatives to controversial political battlegrounds.
-
Paramedics in the Denver area will be administering an experimental blood substitute to patients who meet certain criteria under an unusual research protocol that allows patients to be recruited without giving informed consent.
-
An experimental blood oxygenation device has the potential to help thousands of patients with severe emphysema or other lung conditions. The device has been thoroughly tested in laboratory animals, but human trials would involve major invasive procedures for research participants and place them at very high risk of death or serious complications.
-
-
Knowledge is power, and knowing how an audit works can help you sail through, says Erich K. Jensen. Jensen has developed a course designed specifically to highlight what happens during an FDA audit and what can be done to make the process as easy as possible.
-
Just about a year ago, the Privacy Rule, which is a part of the Health Insurance Portability and Accountability Act (HIPAA) regulations, became enforceable. Already, complaints are coming in and investigations are being launched some against mighty organizations such as Kaiser Permanente.
-
Federal laws aimed at encouraging drug companies to study how well their products work in children have had the unintended consequence of weakening already vague protections that prevent child research subjects from being exploited, a leading human subjects research advocate claims.
